It is not used as a therapeutic agent by itself but as a diluent or reconstitution medium for injectable medications such as peptides, hormones like HGH, and antibiotics
investigated for selective fat-mobilising effects independent of GH receptor signalling Cartilage & joint research Examined in chondrocyte models and osteoarthritis frameworks for anabolic effects on cartilage matrix synthesis Metabolic profile Investigated for absence of the hyperglycaemic and IGF-1-elevating effects associated with full-length hGH, making it a useful tool compound for isolating GHs metabolic effects Body composition models Studied in rodent obesity models for changes in fat mass, lean mass, and energy expenditure Clinical research history Progressed to early-phase human trials in Australia (2000s) for obesity and osteoarthritis indications
Combining Peptides in One Injection Some peptides can be safely combined into a single syringe to reduce the total number of injections
Quick Facts TypePeptide Blend (BPC-157 + TB-500) CategoryRecovery / Tissue Repair AdministrationSubcutaneous injection FrequencyDaily (loading) / 3x weekly (maintenance) Typical Dose250500 mcg of each per dose Cycle Length48 weeks Available Sizes5 mg/5 mg (10 mg total) vials Stability21 days after reconstitution Overview What is the BPC-157 / TB-500 Blend
The clinic treats a broad range of conditions, reflecting Dr
Check expiration dates carefully, as compounded medications generally have shorter beyond-use dates than FDA-approved products
